Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 2.36M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 43K
10: EX-10.101 Material Contract HTML 340K
3: EX-10.28 Material Contract HTML 59K
4: EX-10.32 Material Contract HTML 41K
5: EX-10.33 Material Contract HTML 84K
6: EX-10.34 Material Contract HTML 38K
7: EX-10.35 Material Contract HTML 78K
8: EX-10.36 Material Contract HTML 38K
9: EX-10.37 Material Contract HTML 63K
11: EX-21 Subsidiaries List HTML 29K
12: EX-23.1 Consent of Expert or Counsel HTML 34K
17: EX-97 Clawback Policy re: Recovery of Erroneously HTML 42K
Awarded Compensation
13: EX-31.1 Certification -- §302 - SOA'02 HTML 34K
14: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
15: EX-32.1 Certification -- §906 - SOA'02 HTML 31K
16: EX-32.2 Certification -- §906 - SOA'02 HTML 31K
23: R1 Cover Page HTML 95K
24: R2 Audit Information HTML 34K
25: R3 Consolidated Statements of Operations HTML 111K
26: R4 Consolidated Statements of Comprehensive Loss HTML 56K
27: R5 Consolidated Balance Sheets HTML 143K
28: R6 Consolidated Balance Sheets (Parenthetical) HTML 46K
29: R7 Consolidated Statements of Changes in HTML 85K
Stockholders' Equity (Deficit)
30: R8 Consolidated Statements of Changes in HTML 32K
Stockholders' Equity (Deficit) (Parenthetical)
31: R9 Consolidated Statements of Cash Flows HTML 123K
32: R10 Organization & Business HTML 34K
33: R11 Summary of Significant Accounting Policies HTML 120K
34: R12 Revenue HTML 107K
35: R13 Collaboration, License, and Supply Agreements HTML 47K
36: R14 Cash, Cash Equivalents, and Restricted Cash HTML 42K
37: R15 Fair Value Measurements HTML 65K
38: R16 Inventory HTML 46K
39: R17 Goodwill HTML 37K
40: R18 Leases HTML 154K
41: R19 Long-Term Debt HTML 70K
42: R20 Stockholders? Deficit HTML 39K
43: R21 Stock-Based Compensation HTML 97K
44: R22 Employee Benefits HTML 35K
45: R23 Other Financial Information HTML 64K
46: R24 Income Taxes HTML 120K
47: R25 Commitment and Contingencies HTML 53K
48: R26 Restructuring HTML 39K
49: R27 Subsequent Events HTML 32K
50: R28 Pay vs Performance Disclosure HTML 41K
51: R29 Insider Trading Arrangements HTML 48K
52: R30 Summary of Significant Accounting Policies HTML 159K
(Policies)
53: R31 Summary of Significant Accounting Policies HTML 65K
(Tables)
54: R32 Revenue (Tables) HTML 84K
55: R33 Cash, Cash Equivalents, and Restricted Cash HTML 41K
(Tables)
56: R34 Fair Value Measurements (Tables) HTML 63K
57: R35 Inventory (Tables) HTML 47K
58: R36 Goodwill (Tables) HTML 39K
59: R37 Leases (Tables) HTML 93K
60: R38 Long-Term Debt (Tables) HTML 51K
61: R39 Stock-Based Compensation (Tables) HTML 95K
62: R40 Other Financial Information (Tables) HTML 72K
63: R41 Income Taxes (Tables) HTML 122K
64: R42 Restructuring (Tables) HTML 36K
65: R43 Summary of Significant Accounting Policies - HTML 94K
Additional Information (Details)
66: R44 Summary of Significant Accounting Policies - HTML 54K
Schedule of Concentration Risk (Details)
67: R45 Summary of Significant Accounting Policies - HTML 39K
Schedule of Property and Equipment (Details)
68: R46 Revenue - Additional Information (Details) HTML 201K
69: R47 Revenue - Schedule of Accounts Receivable, HTML 73K
Unbilled Services, and Deferred Revenue (Details)
70: R48 Revenue - Schedule of Product Revenue (Details) HTML 48K
71: R49 Revenue - Schedule of Revenue Gross to Net HTML 48K
Deductions Balances (Details)
72: R50 Revenue - Schedule of Grant Revenue (Details) HTML 49K
73: R51 Collaboration, License, and Supply Agreements HTML 87K
(Details)
74: R52 Cash, Cash Equivalents, and Restricted Cash - HTML 41K
Schedule of Reconciliation of Cash, Cash
Equivalents, and Restricted Cash (Details)
75: R53 Fair Value Measurements (Details) HTML 72K
76: R54 Inventory - Schedule of Inventory (Details) HTML 37K
77: R55 Inventory - Additional Information (Details) HTML 39K
78: R56 Inventory - Schedule of Inventory Reserves HTML 37K
(Details)
79: R57 Goodwill (Details) HTML 39K
80: R58 Leases - Additional Information (Details) HTML 60K
81: R59 Leases - Schedule of Supplemental Balance Sheet HTML 68K
Information Related to Leases (Details)
82: R60 Leases - Schedule of Operating Lease Expenses HTML 44K
(Details)
83: R61 Leases - Schedule of Supplemental Cash Flow HTML 41K
Information of Leases (Details)
84: R62 Leases - Maturities of Lease Liabilities (Details) HTML 48K
85: R63 Long-Term Debt - Schedule of Notes Payable HTML 55K
(Details)
86: R64 Long-Term Debt - Schedule of Interest Expense HTML 38K
(Details)
87: R65 Long-Term Debt - Additional Information (Details) HTML 105K
88: R66 Stockholders? Deficit (Details) HTML 75K
89: R67 Stock-Based Compensation - Additional Information HTML 92K
(Details)
90: R68 Stock-Based Compensation - Schedule of Stock-Based HTML 39K
Compensation Expense (Details)
91: R69 Stock-Based Compensation - Schedule of Option and HTML 71K
Appreciation Rights Activity (Details)
92: R70 Stock-Based Compensation - Schedule of Assumptions HTML 59K
Used in Estimation of Fair Value of Stock
(Details)
93: R71 Stock-Based Compensation - Schedule of Restricted HTML 61K
Stock Units Activity (Details)
94: R72 Employee Benefits (Details) HTML 46K
95: R73 Other Financial Information - Schedule of Prepaid HTML 36K
Expenses and Other Current Assets (Details)
96: R74 Other Financial Information - Schedule of Property HTML 49K
and Equipment, Net (Details)
97: R75 Other Financial Information - Additional HTML 37K
Information (Details)
98: R76 Other Financial Information - Schedule of Accrued HTML 41K
Expenses (Details)
99: R77 Other Financial Information - Schedule of Other HTML 37K
Current Liabilities (Details)
100: R78 Income Taxes - Schedule of Company's Income (Loss) HTML 39K
from Operations Before Income Tax Provision
(Benefit) by Jurisdiction (Details)
101: R79 Income Taxes - Schedule of Components of Income HTML 48K
Tax Expense (Benefit) (Details)
102: R80 Income Taxes - Additional Information (Details) HTML 54K
103: R81 Income Taxes - Schedule of Tax Rate Differences HTML 58K
(Details)
104: R82 Income Taxes - Schedule of Deferred Tax Assets and HTML 79K
Liabilities (Details)
105: R83 Income Taxes - Schedule of Unrecognized Tax HTML 41K
Benefits Rollforward (Details)
106: R84 Commitment and Contingencies (Details) HTML 71K
107: R85 Restructuring - Schedule of Impairment Charges HTML 45K
(Details)
108: R86 Restructuring - Narrative (Details) HTML 42K
109: R87 Subsequent Events (Details) HTML 34K
111: XML IDEA XML File -- Filing Summary XML 188K
114: XML XBRL Instance -- nvax-20231231_htm XML 2.30M
110: EXCEL IDEA Workbook of Financial Report Info XLSX 229K
19: EX-101.CAL XBRL Calculations -- nvax-20231231_cal XML 249K
20: EX-101.DEF XBRL Definitions -- nvax-20231231_def XML 949K
21: EX-101.LAB XBRL Labels -- nvax-20231231_lab XML 2.46M
22: EX-101.PRE XBRL Presentations -- nvax-20231231_pre XML 1.48M
18: EX-101.SCH XBRL Schema -- nvax-20231231 XSD 235K
112: JSON XBRL Instance as JSON Data -- MetaLinks 654± 960K
113: ZIP XBRL Zipped Folder -- 0001000694-24-000007-xbrl Zip 1.03M
I am pleased to offer you the full-time position of Executive Vice President & Chief Strategy Officer at Novavax, Inc
In this position you will report John C Jacobs, President & Chief Executive Officer. Your first day of employment is expected to be on or about March 1,2023
This offer is contingent upon the following:
•Successful and satisfactory completion of our standard background check All information provided by you in your employment application, interviews. and any other verbal or written correspondence will be verified by a third-party background checking company or by Novavax. Any discrepancies found may delay your start date or could potentially cause withdrawal of this offer. Candidates cannot begin employment until the background check is completed, including verification of current employment.
•Your disclosure of all contractual
or other obligations owed by you to previous employers or other parties that would in any way limit your ability to perform your job at the Company. If there are any obligations that might limit your ability to perform, such matters must be disclosed and addressed by the Company prior to commencement of employment.
•Compliance with the Novavax COVID-19 Vaccination Policy for US Employees. which may include providing proof of vaccination at the time you begin working or requesting an accommodation or exemption. A copy of the policy is attached for your review If you need an accommodation or believe you are exempt due to applicable state law, please email our Benefits Team at NovavaxBenetits@novavax.com.
•Execution
of the Employment Agreement, a copy of which is enclosed for your review.
•Successful verification of your employment eligibility in the United States. To verify this information, please be prepared to produce acceptable documents. BY FEDERAL LAW, IT IS REQUIRED THAT YOU PRESENT THIS DOCUMENTATION WITHIN THREE DAYS OF YOUR START AT WORK.
The specific of this offer are outlined in the enclosed Employment Agreement and include the following:
SALARY: Your initial annualized base salary will be $520,000 per year, payable semi-monthly, less applicable payroll taxes and authorized deductions.
BONUS PROGRAM
You will be eligible to participate in the Company's annual incentive bonus program, under which award payments, if any, will be based on performance criteria and milestones to be determined by the Company. You will be paid in the following year in which the compensation is earned. Your bonus at 100% of target will be 50% of your earnings for the
performance year. The bonus shall be paid out partly in cash and partly in shares of stock options or restricted stock, at the discretion of the Board of Directors.
COMMUTING ALLOWANCE:
During the term of your employment, the Company will provide a monthly commuting allowance of up to $5,000 for the cost of housing and other related commuting expenses incurred by you to commute between your home in [ * * * ] and the Company's Gaithersburg offices (the "Allowance") In addition, the Company will pay an additional sum to reimburse you for the personal income taxes associated with the Allowance, such that the economic benefit is the same as if such Allowance were provided on a non-taxable basis.
INITIAL EOUlTY
GRANT: As soon as reasonably practicable following your start date and subject to the approval of the Board of Directors or the Compensation Committee. as a material inducement to commence employment with the Company and in accordance with Nasdaq Listing Rule 5635(c)(4), you will receive an initial stock option grant of 67,900 shares ('Inducement Stock Options") and an initial grant of 58,800 restricted stock units ('Inducement Restricted Stock Units") The Inducement Restricted Stock Units will vest as to one-third (1/3) of the shares underlying the Inducement Restricted Stock Units on each of the first three (3) anniversaries of the date of grant. in each case subject to your
continued employment with the Company through the applicable vesting date. The Inducement Stock Options will vest as to one-quarter (1/4) of the shares underlying the Inducement Stock Options on the first anniversary of the date of grant and as to the remaining shares in equal monthly installments for thirty-six (36) months thereafter, in each case subject to your continued employment with the Company through the applicable vesting date. Each of the Inducement Restricted Stock Units and Inducement Stock Options will be granted under and subject to the terms of the Company's inducement equity plan and an agreement in substantially the form of a restricted stock unit agreement or the form of a stock option award
agreement, as applicable, previously approved by the Board of Directors or the Compensation Committee.
ANNUAL EQUITY GRANTS: Beginning in 2024, you will be eligible to receive an additional annual equity award based upon performance and subject to the approval of the Board of Directors or the Compensation Committee.
Your employment and compensation with Novavax are "at will". At will employment is defined as an employee/employer relationship which may be ended by either the employee or employer at any time. without cause, except as otherwise provided by law or defined in the terms of the Employment Agreement.
Elaine, if you agree with and accept the terms of this offer letter
and the Employment Agreement, please sign below and return this letter and the Employment Agreement to my office. We are confident your employment with Novavax will prove mutually beneficial. and we look forward to you joining the Novavax team.
